Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222
暂无分享,去创建一个
G. Ogg | G. Malavige | T. Tan | L. Schimanski | C. Jeewandara | D. Guruge | D. Jayathilaka | P. Pushpakumara | R. Wijayamuni | L. Gomes | A. Wijewickrama | I. Aberathna | S. Danasekara | H. Kuruppu | T. Ranasinghe | Alain Townsend | T. Jayadas | A. Kamaladasa | Gayasha Somathilake | Buddini Gunathilaka
[1] L. Abu-Raddad,et al. Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections , 2021, The New England journal of medicine.
[2] P. Simmonds,et al. Comparability of six different immunoassays measuring SARS‐CoV‐2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction , 2021, Transfusion.
[3] G. Ogg,et al. Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers , 2021, Nature Communications.
[4] G. Ogg,et al. Comparison of two assays to detect IgG antibodies to the receptor binding domain of SARS‑CoV‑2 as a surrogate marker for assessing neutralizing antibodies in COVID-19 patients , 2021, International Journal of Infectious Diseases.
[5] R. Selvarangan,et al. Cross-reactive antibody immunity against SARS-CoV-2 in children and adults , 2021, Cellular & Molecular Immunology.
[6] Gareth Iacobucci. Covid-19: Single vaccine dose is 33% effective against variant from India, data show , 2021, BMJ.
[7] L. Abu-Raddad,et al. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.
[8] Scott L. Bain,et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study , 2021, The Lancet.
[9] G. Ogg,et al. Antibody and T-cell responses to a single dose of the AZD1222/Covishield vaccine in previously SARS-CoV-2 infected and naive health care workers in Sri Lanka , 2021, medRxiv.
[10] A. Wisnewski,et al. Human IgG and IgA responses to COVID-19 mRNA vaccines , 2021, medRxiv.
[11] K. Mølbak,et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study , 2021, The Lancet.
[12] R. Rubin. COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough. , 2021, JAMA.
[13] N. G. Davies,et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, Nature.
[14] N. Jewell,et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, medRxiv.
[15] D. Stuart,et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera , 2021, Cell.
[16] D. Lauffenburger,et al. Humoral signatures of protective and pathological SARS-CoV-2 infection in children , 2021, Nature Medicine.
[17] Nuno R. Faria,et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence , 2021, The Lancet.
[18] J. Dubuisson,et al. Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals , 2020, Frontiers in Microbiology.
[19] P. Klenerman,et al. A haemagglutination test for rapid detection of antibodies to SARS-CoV-2 , 2020, Nature Communications.
[20] K. Järvinen,et al. Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk , 2020, Journal of Perinatology.
[21] Guozhong Zhang,et al. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19 , 2020, Signal Transduction and Targeted Therapy.
[22] G. Ogg,et al. SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness , 2020, Scientific Reports.
[23] Francisco A. Chaves,et al. S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit , 2020, mBio.
[24] O. Schwartz,et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2 , 2020, Science Translational Medicine.
[25] M. Roser,et al. Coronavirus Pandemic (COVID-19) , 2020 .
[26] Christopher Earl,et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans , 2020, Science.
[27] H. Hakonarson,et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients , 2020, European Respiratory Journal.
[28] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.